Inflammation and oxidative stress in ESRD - The role of myeloperoxidase

Journal of Nephrology

Volumn 17, Issue SUPPL. 8, 2004, Pages

  Maruyama, Yukio ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; End stage renal disease; Inflammation; Malnutrition; Myeloperoxidase; Oxidative stress

Indexed keywords

HYPOCHLORITE; MYELOPEROXIDASE; NITRIC OXIDE; ANTIOXIDANT; AUTACOID; PEROXIDASE;

ALLELE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEREDITY; HUMAN; KIDNEY FAILURE; NEPHRITIS; NEUTROPHIL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ARTERIOSCLEROSIS; CHRONIC KIDNEY FAILURE; GENETICS; INFLAMMATION; METABOLISM; NUTRITIONAL STATUS; PATHOLOGY; RISK FACTOR;

ANTIOXIDANTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; NUTRITIONAL STATUS; OXIDATIVE STRESS; PEROXIDASE; RISK FACTORS;

EID: 16644380089     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Tommy Cederholm T, Girndt M. IL-10, IL-6 and TNF-α: central factors in the altered cytokine network of uremia - the good, the bad and the ugly. Kidney Int 2005 (in press).
2. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-38.
3. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallai GE, Lewin NW. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-6.
4. Witko-Sarsat V, Friedlander M, Khoa TN, Capeillére-Blandin C, Nguyen AT, Canteloup S. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.
5. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
6. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin A, Marchais SJ. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-7.
7. Bayés B, Pastor C, Bonal J, Juncá J, Hernandez JM, Riutort N. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-12.
8. Stenvinkel P, Diczfalusy U, Lindholm B, Heimbürger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased mortality in patients on renal replacement therapy. Nephrol Dial Transplant 2004; 19: 972-6.
9. Himmelfarb J, McMenamin E, Loseto G, Heinecke JW. Myeloperoxidase- catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163-9.
10. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marcgal V, Gothot A. Consequences of total and subtotal myeloperoxidases: risk or benefit? Acta Haematol 2000; 104: 10-5.
11. Brennan M-L, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003; 14: 353-9.
12. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296: 2391-4.
13. Kaysen GA, Eiserich JP. The role of oxidative stress - altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004; 15: 538-48.
14. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
15. Zhang R, Brennan M-L, Fu X, Aviles RJ, Pearce GL, Penn MS. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-42.
16. Baldus S, Heeshen C, Meinertz T, Zeiher AM, Eisreich JP, Münzel T. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-5.
17. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-604.
18. Makela R, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, Jaakkola O. Myeloperoxidase gene variation and coronary flow reserve in young healthy men. J Biomed Sci 2004; 11: 59-64.
19. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphism variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001; 142: 336-9.
20. Makela R, Karhunen PJ, Kunnas TA, Ilveskoski E, Kajander OA, Mikkelsson J. Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study. Lab Invest 2003; 83: 919-25.
21. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimbürger O, Barany B, Hoff C. A functional variant in the myeloperoxidase (MPO) gene is associated with cardiovascular disease (CSTJ) in end-stage renal disease (ESRD) patients. Kidney Int 2003; 84: 172-6.
22. Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int 2003; 64: 1956-67.
23. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-911.
24. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31: 93-100.
25. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
26. Kaizu Y, Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42: 295-302.
27. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-82.
28. Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
29. Danielski M, Ikizler TA, McMonagle E, Kane JC, Pupim L, Morrow J. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. AmJ Kidney Dis 2003; 42: 286-94.
30. Stenvinkel P, Holmberg I, Heimbürger O, Diczfalusy U. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998; 13: 2594-600.
31. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150: 217-24.
32. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-18.
33. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361: 2017-23.
34. Mann JFE, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney Int 2004; 65: 1375-80.
35. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105: 2107-11.
36. Smith KS, Lee CL, Ridlington JW, Leonard SW, Devaraj S, Traber MG. Vitamin E supplementation increases circulating vitamin E metabolites tenfold in end-stage renal disease patients. Lipids 2003; 38: 813-9.
37. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 2003; 64: 978-91.
38. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-7.
39. Brunet J, Boily MJ, Cordeau S, Des Rosiers C. Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radic Biol Med 1995; 19: 627-38.
40. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drücke T, Santangelo F. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91.
41. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 2003; 107: 992-5.
42. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109: 369-74.
43. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett 2003; 226: 195-202.
44. Dawson R, Biasetti M, Messina S, Dominy J. The cytoprotective role of taurine in exercise-induced muscle injury. Amino Acids 2002; 22: 309-24.